---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049044"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:46:01.036378+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kezar licenses zetomipzomib to Everest for up to $132.5M in Greater China & SE Asia

## Summary
- Kezar receives $7.0M upfront; eligible for up to $132.5M in development, regulatory & commercial milestones.
- Everest gets exclusive rights to develop and commercialize zetomipzomib for non-oncology uses in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines.
- Parties will collaborate on PALIZADE Phase 2b lupus nephritis trial; Everest contributes local expertise and covers costs in licensed territories.
- Tiered royalties from single-digit to low-teens on net sales; Kezar supplies drug with Everest option to manufacture after PALIZADE.

## SEC filing metadata
- accession: 0000950170-23-049044
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023049044/0000950170-23-049044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023049044/kzr-20230920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049044
- JSON: https://secwatch.observer/filing/0000950170-23-049044.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049044.txt

## Key facts
- Material Agreements
  Kezar Life Sciences, Inc. entered into Collaboration and License Agreement with Everest Medicines II (HK) Limited valued at initial upfront payment of $7.0 million; potential milestone payments of up to $125.5 million; tiere (effective 2023-09-20).
  - Action: entry
  - Agreement: license
  - Counterparty: Everest Medicines II (HK) Limited
  - Value: initial upfront payment of $7.0 million; potential milestone payments of up to $125.5 million; tiere
  - Effective: 2023-09-20
  source text: On September 20, 2023, Kezar Life Sciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “License Agreement”) with Everest Medicines II (HK) Limited (“Everest”) pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company’s proprietary compound, zetomipzomib (collectively, the “Products”), in the licensed field in the greater China region (mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the “Territory”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023049044/0000950170-23-049044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.